JBM (HEALTHCARE) LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.97 HKD | +12.79% |
|
+12.50% | -5.71% |
| Sales 2022 | 406M 52M 4.14B | Sales 2023 | 520M 66.61M 5.31B | Capitalization | 987M 126M 10.07B |
|---|---|---|---|---|---|
| Net income 2022 | 24M 3.07M 245M | Net income 2023 | 57M 7.3M 582M | EV / Sales 2022 | 2.33 x |
| Net Debt 2022 | 134M 17.14M 1.37B | Net Debt 2023 | 16.62M 2.13M 170M | EV / Sales 2023 | 1.93 x |
| P/E ratio 2022 |
33
x | P/E ratio 2023 |
16.9
x | Employees | 258 |
| Yield 2022 * |
-
| Yield 2023 |
2.78% | Free-Float | 16.55% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +15.12% | ||
| 1 week | +12.50% | ||
| Current month | +13.79% | ||
| 1 month | +8.79% | ||
| 3 months | +2.06% | ||
| 6 months | -11.61% | ||
| Current year | -5.71% |
1 week
0.86
1.04
1 month
0.861.04
Current year
0.861.06
1 year
0.771.30
3 years
0.582.33
5 years
0.583.20
10 years
0.583.20
| Managers | Title | Age | Since |
|---|---|---|---|
Yat Wai Wong
CEO | Chief Executive Officer | 61 | 06/01/20 |
Kau Lap Lam
DFI | Director of Finance/CFO | 38 | 31/01/22 |
Hoi Ki Leung
PRN | Corporate Officer/Principal | 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Leung Yim
BRD | Director/Board Member | 62 | 21/09/20 |
Kwong Yip Sum
CHM | Chairman | 61 | 21/09/20 |
Yat Wai Wong
CEO | Chief Executive Officer | 61 | 06/01/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 0.97 | +12.79% | 594 000 |
| 03/05/24 | 0.86 | -2.27% | 190,027 |
| 02/05/24 | 0.88 | +1.15% | 42,000 |
| 30/04/24 | 0.87 | -1.14% | 48,000 |
| 29/04/24 | 0.88 | 0.00% | 129,198 |
Delayed Quote Hong Kong S.E., May 06, 2024 at 02:41 am
More quotes
JBM Healthcare Ltd is an investment holding company mainly engages in the marketing and distribution of proprietary Chinese medicines. The Company operates its business through three segments. The Proprietary Chinese Medicines segment mainly distributes over the counter (OTC) proprietary Chinese medicines and concentrated Chinese medicine granule (CCMG) products. The Consumer Healthcare Products segment primarily distributes proprietary medicines in the form of OTC. The Health and Wellness Products segment sales and distributes health and wellness products. The Company operates business in domestic and overseas markets such as Southeast Asia, Europe, and North America.
Sector
Pharmaceuticals
Calendar
25/06/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.71% | 91.16M | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.19B | |
| +3.98% | 3.15B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- 2161 Stock
